Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.

Int J Infect Dis · 2022 · PMC9422336 · PMID 36049700

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The live-virus neutralization assay 28 days after the second dose showed a trend of decreasing immune responses to the vaccine as age increases.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.